Medication Development in Alcoholism: Investigating PPAR Agonists

NCT ID: NCT02158273

Last Updated: 2017-06-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary hypotheses under test are that alcohol dependent subjects treated with fenofibrate will report decreased craving for alcohol following cue-exposure in the laboratory and report less drinking post treatment relative to placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcoholism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TRICOR (fenofibrate)

Group Type ACTIVE_COMPARATOR

TRICOR (fenofibrate)

Intervention Type DRUG

145 mg/day, oral pill, 9 days

Sugar Pill

Group Type PLACEBO_COMPARATOR

Sugar Pill

Intervention Type DRUG

145 mg/day, oral pill, 9 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sugar Pill

145 mg/day, oral pill, 9 days

Intervention Type DRUG

TRICOR (fenofibrate)

145 mg/day, oral pill, 9 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fenofibrate Fenoglide Trilipix Lipofen

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female volunteers, 18-65 years of age
* Meets DSM-V criteria for Alcohol Use Disorder ≥ moderate severity and DSM-IV criteria for current alcohol dependence
* Subjects will not be seeking treatment because the medication studies are not treatment trials
* Subjects must be abstinent a minimum of 3 days (but not more than 7 days) prior to the human lab session
* Negative BAC and a CIWA score of \< 9 at screening and time of lab session to eliminate acute alcohol or withdrawal effects on dependent measures
* In acceptable health in the judgment of the study physician, on the basis of interview, medical history, physical exam, ECG, urine test and lab tests
* Females with childbearing potential must have a negative serum pregnancy test on the screening visit with a negative urine pregnancy test at randomization and agree to use an effective method of birth control for the study duration and two weeks thereafter.
* Subjects must be able to complete and understand questionnaires and study procedures in English and sign an informed consent
* Willingness to comply with the provisions of the protocol and take daily oral medication

Exclusion Criteria

* Subjects with a medical condition that contraindicates the administration of fenofibrate or that will increase potential risk as determined by the Study Physician.
* GGT more than 3 times the upper limit of normal
* Female subjects with childbearing potential who are pregnant, nursing, or refuse to use an effective method of birth control for the duration of the study and two weeks thereafter
* Meets DSM-V criteria for a major Axis I disorder including mood or anxiety disorders or substance use disorders (e.g., cocaine, amphetamines, heroin, PCP) other than alcohol or nicotine
* Has a positive UDS at screening or Visit 3 (laboratory session)
* Treatment within the month prior to screening with an investigational drug, vaccine or drugs that may influence study outcomes, or drugs that may pose a safety risk as determined by the Study Physician.
* History of hypersensitivity to the study drugs or the ingredients
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

Sponsor Role collaborator

The Scripps Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Barbara J. Mason

PI

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Barbara J. Mason, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

The Scripps Research Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Susan Quello

La Jolla, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01AA012602

Identifier Type: NIH

Identifier Source: secondary_id

View Link

AA012602-14A1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Novel Compound for Alcoholism Treatment
NCT02039349 COMPLETED PHASE1
Effect of LY686017 on Alcohol Craving
NCT00310427 COMPLETED PHASE2
CRF1 Antagonist GSK561679 in Alcoholism
NCT01187511 COMPLETED PHASE2
PT150 Drug for Use in Alcohol Use Disorder
NCT06712602 RECRUITING PHASE1
Minocycline for Alcohol Use Disorder
NCT03244592 WITHDRAWN PHASE1/PHASE2
Semaglutide for Alcohol Use Disorder
NCT05520775 COMPLETED PHASE2